Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cantharidin (Primary)
  • Indications Molluscum contagiosum
  • Focus Registrational; Therapeutic Use
  • Acronyms CAMP-2
  • Sponsors Verrica Pharmaceuticals

    • Most Recent Events

    • 21 Jul 2023 According to a Verrica Pharmaceuticals media release, based on the data of CAMP-1 and CAMP-2 studies, the USA Food and Drug Administration (FDA) approval of YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.
    • 27 Feb 2023 According to a Verrica Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) accepted for resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 23, 2023.
    • 11 Aug 2022 According to a Verrica Pharmaceuticals media release, company expect to be able to resubmit the NDA for VP-102 for the treatment of molluscum contagiosum (molluscum) in the first quarter of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top